Company Description
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States.
The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.
It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.
In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral β-lactam antibiotics.
It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d’Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004.
Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 2001 |
| IPO Date | Jun 26, 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Steven Shallcross |
Contact Details
Address: 9605 Medical Center Drive, Suite 270 Rockville, Maryland 20850 United States | |
| Phone | 301 417 4364 |
| Website | therivabio.com |
Stock Details
| Ticker Symbol | TOVX |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000894158 |
| ISIN Number | US87164U4094 |
| Employer ID | 13-3808303 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Steven A. Shallcross CPA | Chief Executive Officer, Chief Financial Officer, Treasurer, Corporate Secretary and Director |
| Dr. Vince Wacher Ph.D. | Head of Product and Corporate Development |
| Dr. Michael Kaleko M.D., Ph.D. | Senior Vice President of Research and Development |
| Dr. Ramon Alemany Ph.D. | Senior Vice President of Discovery and Chairman of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 5, 2024 | 8-K | Current Report |
| Nov 20, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 1, 2024 | 8-K | Current Report |
| Oct 16, 2024 | 8-K | Current Report |
| Oct 3, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 3, 2024 | 8-K | Current Report |
| Oct 2, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |